Novel Drug May Reduce Risk of HIV-Associated Neurocognitive Disorders

Article

Many patients with HIV develop neurocognitive disorders, which is incurable.

Up to half of people living with HIV (PLWH) experience HIV-associated neurocognitive disorders (HAND), a neurological manifestation of HIV-1 infection. HAND appears to manifest pursuant to persistent central nervous system inflammation, anomalous macrophage activation, and increased oxidative stress.

Researchers are interested in finding therapies that are neuroprotective and have screened thousands of compounds that are commercially available. Two compounds/classes—fluconazole and selective serotonin reuptake inhibitors—seem to protect hippocampal neurons. Furthermore, previous screenings suggested that when given together, their actions may be synergistic.

Researchers from the Johns Hopkins University School of Medicine in Baltimore, MD, conducted a study of the paroxetine and fluconazole, including 45 adult PLWH experiencing HAND. Their results, published in the Journal of Neural Virology, indicate that paroxetine was able to improve some neuropsychological test measures, but fluconazole had little benefit.

For more information, please visit PharmacyTimes.com.

Related Videos
Atopic dermatitis on a patient's hand -- Image credit: Ольга Тернавская | stock.adobe.com
biosimilar word or concept represented by wooden letter tiles on a wooden table with glasses and a book | Image Credit: lexiconimages - stock.adobe.com
Image credit: alicja neumiler | stock.adobe.com
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
HIV awareness
Laboratory test tubes and solution with stethoscope background | Image Credit: Shutter2U - stock.adobe.com
Image credit: Krakenimages.com | stock.adobe.com
Human brain digital illustration. Electrical activity, flashes, and lightning on a blue background. | Image Credit: Siarhei - stock.adobe.com
Physician and kidneys
© 2024 MJH Life Sciences

All rights reserved.